The 3rd Joint Meeting of the Association of British Clinical Diabetologists and the Renal Association
Diabetes and Kidney Disease: Advances and Controversies
Tuesday Feb 28th 2017, National Exhibition Centre, Birmingham
Although advances have been made in the management of many diabetes related complications, rates of diabetic nephropathy have not changed despite the implementation of several interventions. Despite NICE guidance and QoF targets, optimal management that improves outcomes still eludes us.
This meeting brings together internationally renowned leaders in the field of diabetes related renal disease to discuss current challenges, future potential areas for intervention, and therapeutic opportunities. We are delighted that Dr Chistoph Wanner will be joining us as a lead investigator from the EMPA-REG study to focus on the renal outcomes from this and other recent cardiovascular outcome studies. This meeting will premiere new national guidelines for the management of diabetes in chronic kidney disease (CKD), updates on glycaemic assessment in CKD with anaemia , pancreas–renal transplantation , quality of life and cognitive dysfunction in end stage renal disease in diabetes , and nutriotionla care in diabetes and advanced renal disease.
We are particularly pleased to invite junior medical and allied health care professionals to attend the meeting at highly discounted rates.
Who should attend?
- Consultants in diabetes
- Consultants in renal disease
- General physicians and GPs with an interest in diabetes and kidney disease
- Trainees and specialist nurses in diabetes or nephrology who have an interest in diabetes related renal disease.
- Dietitians and podiatrists with an interest in diabetic renal disease
- Those who are looking to learn more about the challenges posed by diabetic nephropathy and CKD and current innovations and challenges
PLEASE NOTE EARLY BIRD RATES ARE NO LONGER AVAILABLE, PLEASE SEE CURRENT RATES BELOW:
This meeting has been funded by unrestricted educational grants from Astra Zeneca, Boehringer Ingelheim, Eli Lilly & Co Ltd, Janssen, Merck Sharp & Dohme, Novo Nordisk, Takeda UK Ltd, Vifor Pharma Ltd.
United Kingdom
Consultant member | £200.00 |
Commercial (non-sponsor company) | £400.00 |
Sponsor company personnel (additional to those included in sponsorship package) | £200.00 |
Commercial (non-sponsor company) | £400.00 |
Commercial (non-sponsor company) | £400.00 |
Consultant non-member | £275.00 |
Trainee member or non-member | £50.00 |
Retired | £125.00 |
Sponsor company personnel (additional to those included in sponsorship package) | £200.00 |
Allied healthcare professional | £50.00 |
Sponsor company personnel (additional to those included in sponsorship package) | £200.00 |
Sponsor company personnel (additional to those included in sponsorship package) | £200.00 |
Commercial (non-sponsor company) | £400.00 |
Commercial (non-sponsor company) | £400.00 |
Event Additionals
|
Event Certificate Details
|